Navigation Links
Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
Date:12/5/2010

a (SLL): An Update on Ongoing Phase 1 Studies" is being presented by Jan Burger MD, PhD. This abstract describes clinical data from a pooled analysis of 54 CLL/SLL patients from a Phase Ia (N=16) and a Phase Ib/II (N=38) study.  Patients from the Phase Ia trial have relapsed/refractory CLL/SLL and have been treated for a median of approximately 8 months, while patients on the Phase Ib/II trial include two cohorts—one with relapsed or refractory disease and one with treatment-naive disease—who were just recently enrolled.

Response data from the pooled analysis is presented below.  Outcomes are described based on strict application of standard response criteria, with an additional outcome category termed "nodal response with lymphocytosis." This category describes patients with substantial lymph node (LN) shrinkage who have not yet achieved a 50% decrease of malignant B cells in the blood (lymphocytosis). The inclusion of this category is necessary because of the unique characteristics of response to this agent, especially early in treatment.  From the Ia trial, with approximately 8 months median follow-up, 1 patient achieved a complete response (CR) and 8/13 evaluable patients achieved a partial response (PR) for an objective response rate of 69%. Two additional patients achieved a nodal response with lymphocytosis (15%) and 2 patients had stable disease (SD).  Of note, 3 of the patients now classified as partial responses were initially nodal response with lymphocytosis earlier in treatment. In the Ib/II trial, with less than 2 months median follow-up, 8/32 evaluable patients achieved a PR (25%) by standard response criteria with an additional 17/32 (53%) achieving a nodal response with lymphocytosis.  Six other patients have SD. As noted previously, study of the patients from the Ia trial suggest that blood lymphocytosis decreases over time on treatment and patients who initially are described as nodal responses with lym
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
2. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
3. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
4. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
5. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
6. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
7. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
8. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
11. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of ... Home Medical Equipment, Inc. ("Progressive") of Clarion, PA ... acquisition were not disclosed. Progressive is a ... range of sleep, mobility, and respiratory products to customers in ...
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... financial results for the first quarter ended March 31, 2011 ... financial markets. NxStage will also host a conference ... 2011 to discuss its first quarter financial results. To listen ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that the ... Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) ... neuroendocrine tumors (NET) of pancreatic origin. ... from the everolimus RADIANT (RAD001 In Advanced Neuroendocrine ...
Cached Medicine Technology:NxStage® to Report First Quarter Fiscal 2011 Financial Results 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
(Date:4/24/2014)... negative and stressful outcomes for parents who have a ... illness, says a recent study led by a researcher ... are numerous and life-changing and stress levels high, the ... research reported positive outcomes as well, a phenomenon known ... recent issue of the American Journal of Orthopsychiatry ...
(Date:4/24/2014)... 2014 ,Take me out to the ballgame, doesn,t ... chips. The more likely culprits include French fries, soda ... for children who play youth baseball, eating unhealthy food ... problems, according to researchers at Wake Forest Baptist Medical ... of Childhood Obesity , found that high-calorie snacks ...
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... Fibroblasts, cells long thought to be boring and irrelevant, ... with heart disease. , Researcher Dr Milena Furtado, and ... at Monash University, found the heart cell fibroblast is ... for a healthy beating heart. , In research published ... found that cardiac fibroblasts are unique cells due to ...
(Date:4/24/2014)... of prescription opioid overdose deaths was outlined yesterday in ... leaders of agencies in the U.S. Department of Health ... care providers to expand their use of medications to ... a number of misperceptions that have limited access to ... medications can be used in combination with behavior therapies ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
... The California Veterinary Medical Association (CVMA) warns ... when procedures such as teeth cleaning or therapeutic ... is because special training is necessary and some ... and may require anesthesia. Under California law, only ...
... someday yield therapies to restore sight, experts suggest , , ... plays a major role in two forms of childhood ... researchers. , The discovery of the link between the ... retinitis pigmentosa is important because it pinpoints a new ...
... experts warn , , THURSDAY, March 5 (HealthDay News) -- ... have positive or neutral attitudes toward people who are ... prospective patients, a new study has found. , "Essentially, ... weight bias, and there are negative attitudes toward obese ...
... a national provider of healthcare information technology outsourcing, ... Total Security Program which is designed to offer ... of security services that assess, remediate and monitor ... The Program goes beyond regulated compliance requirements to ...
... Realize New Executive LeadershipKOBE, Japan, March 5 ... leading medical diagnostics instrument manufacturer and laboratory information ... Sysmex Corporate and its subsidiaries in the Americas, ... Kazuya Obe will return to Sysmex Corporate after ...
... headed by Dr. Tom Feasby, Dean of UCalgary,s Faculty ... countries in the number of diagnostic imaging devices, more ... times. The study,s authors say it is critical to ... "This study shows there are important deficiencies in the ...
Cached Medicine News:Health News:Consumers Beware: Unlicensed Care of Animals May Cause Health Problems and Increased Costs 2Health News:Retinal Gene Is Linked to Childhood Blindness 2Health News:Bias Against Obesity Is Found Among Future Dietitians 2Health News:Bias Against Obesity Is Found Among Future Dietitians 3Health News:Phoenix Health Systems Launches Total Security Program for the Healthcare Industry 2Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Lack of strategies to manage MRI wait lists a key reason for excessive wait times 2
... Mesh Self-Forming Plug is a mesh plug ... well as primary inguinal hernias and femoralhernias. ... defect and fills it completely. Premilene Mesh ... of the established Premilene Mesh. The plug ...
... The Celsius Control System provides ... can safely,and rapidly lower patient ... target temperature and,rewarm patients to ... System consists of an endovascular,catheter, ...
... , it maximizes use by allowing ... it, while the third lamp is ... care in mind, it includes universal ... An excellent choice for hospital operating ...
... Perfectly balanced, the patented Orion incorporates ... that illuminates brilliantly. The fully adjustable ... designed to sit low on the brow, ... vision. Two clips on the headband ...
Medicine Products: